GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (FRA:29A) » Definitions » 12-1 Month Momentum %

Amphastar Pharmaceuticals (FRA:29A) 12-1 Month Momentum % : -14.04% (As of Dec. 13, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Amphastar Pharmaceuticals 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-13), Amphastar Pharmaceuticals's 12-1 Month Momentum % is -14.04%.

The industry rank for Amphastar Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:

FRA:29A's 12-1 Month Momentum % is ranked worse than
68.02% of 1063 companies
in the Drug Manufacturers industry
Industry Median: -2.52 vs FRA:29A: -14.04

Competitive Comparison of Amphastar Pharmaceuticals's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amphastar Pharmaceuticals's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's 12-1 Month Momentum % falls into.



Amphastar Pharmaceuticals  (FRA:29A) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amphastar Pharmaceuticals  (FRA:29A) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Amphastar Pharmaceuticals 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amphastar Pharmaceuticals Business Description

Traded in Other Exchanges
Address
11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Amphastar Pharmaceuticals Headlines

No Headlines